Payment overview · 2025
General Payments
$615.24
32 reported records · 11 companies
Healthcare provider profile · identity verified
Sunita Banerjee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PERRYSBURG, OH · NPI 1710993787
Verified facts
What the public records show
CMS Open Payments records show Sunita Banerjee, MD received $615.24 in general payments during 2025 across 32 reported records.
Novo Nordisk Inc accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.79 | 15.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $88.02 | 14.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.19 | 13.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $76.02 | 12.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.35 | 9.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.33 | 8.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $51.87 | 8.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $33.85 | 5.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.27 | 4.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.44 | 3.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $22.11 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $615.24 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $76.02 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.15 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.35 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.98 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $52.33 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $51.87 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.05 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $36.21 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $33.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 73 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
88 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 511 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 103 |
| Lisinopril | Lisinopril | 248 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 247 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 62 |
| Carvedilol | Carvedilol | 196 | 50 |
| Furosemide | Furosemide | 177 | 39 |
| Metformin Hcl | Metformin Hcl | 172 | 43 |
| Omeprazole | Omeprazole | 163 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 45 |
| Losartan Potassium | Losartan Potassium | 117 | 33 |
| Gabapentin | Gabapentin | 113 | 28 |
| Potassium Chloride | Potassium Chloride | 100 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 13 |
| Jardiance | Empagliflozin | 97 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 94 | 26 |
| Trulicity | Dulaglutide | 88 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 33 |
| Famotidine | Famotidine | 80 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 23 |
| Allopurinol | Allopurinol | 73 | 14 |
| Eliquis | Apixaban | 73 | 19 |
| Spironolactone | Spironolactone | 65 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 65 | 17 |
| Bumetanide | Bumetanide | 63 | 13 |
| Ezetimibe | Ezetimibe | 62 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 50 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | 12 |
| Montelukast Sodium | Montelukast Sodium | 42 | 12 |
| Sertraline Hcl | Sertraline Hcl | 42 | 12 |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 13 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 12 |
| Tramadol Hcl | Tramadol Hcl | 34 | suppressed |
| Simvastatin | Simvastatin | 33 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 24 | 11 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 23 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Prednisone | Prednisone | 14 | 13 |
| Unifine Pentips | Pen Needle, Diabetic | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $615.24 · 32 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, REXULTI, Rybelsus, Tymlos, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error